Sugi Predict

Sugi Predict / Compounds / SCHEMBL2441956

SCHEMBL2441956

SCHEMBL2441956

COC(=O)[C@H](CCBr)NC(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 11/20 0.44
▸ CTSS P25774 7/20 0.44
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CTSL P07711 2/20 0.41
▸ CTSB P07858 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ NFKB2 Q00653 1/20 0.41
▸ RELA Q04206 1/20 0.41
▸ KLK5 Q9Y337 1/20 0.41
▸ CA12 O43570 1/20 0.40
▸ CA14 Q9ULX7 1/20 0.40
▸ CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17093839 1.00 CTSK (0.44) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL937622 1.00 CTSK (0.44) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL27133818 0.92 CTSK (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL16387553 0.92 CTSK (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL13422140 0.92 CTSK (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL31240143 0.89 CTSK (0.48) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL16546620 0.89 CTSK (0.48) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL2063018 0.87 CYP1A2 (0.58) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL2063020 0.87 CYP1A2 (0.58) CTSKCTSSCYP1A2CYP2C9CYP2C19
SCHEMBL24073146 0.86 CYP1A2 (0.46) CTSKCTSSCYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119977881-A 2-Hydroxy-6-alkoxy quinoline compound and application thereof 海南大学 2025-05-13 — — CN disclosed
WO-2025072539-A1 AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF PLIANT THERAPEUTICS, INC. (US) 2025-04-03 — — WO disclosed
CN-119504471-A Aryl amino acid derivative of targeting large neutral amino acid transporter 1 and preparation method and application thereof 四川大学华西医院 2025-02-25 — — CN disclosed
US-12110286-B2 Benzimidazolone derived inhibitors of BCL6 CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-10-08 — — US disclosed
CN-118561812-A Benzimidazolone-derived BCL6 inhibitors 癌症研究科技有限公司 2024-08-30 — — CN disclosed
EP-4374858-A2 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 Cancer Research Technology Limited (GB) 2024-05-29 — — EP disclosed
CN-111163839-B Benzimidazolone-derived BCL6 inhibitors 癌症研究科技有限公司 2024-05-28 — — CN disclosed
EP-3630291-B1 BENZIMIDAZOLONE DERIVED INHIBITORS OF BCL6 CANCER RESEARCH TECH LTD (GB) 2024-01-10 — — EP disclosed
CN-112955438-A Protein tyrosine phosphatase inhibitors and methods of use thereof 卡里科生命科学有限责任公司 2021-06-11 — — CN disclosed
EP-3511328-B1 MONOBACTAM ORGANIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS NOVARTIS AG (CH) 2021-03-03 — — EP disclosed
US-7378079-B2 Agents for imaging and diagnostic methods using them NST NEUROSURVIVAL TECHNOLOGIES LTD. (IL) 2008-05-27 — — US disclosed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 — — US disclosed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 — — US disclosed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 — — US disclosed
WO-2007082264-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-19 — — WO disclosed
WO-2007082264-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-19 — — WO disclosed
EP-1606283-A4 P38 INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA INC (US) 2007-05-23 — — EP disclosed
EP-1606283-A2 P38 INHIBITORS AND METHODS OF USE THEREOF Array Biopharma, Inc. (US) 2005-12-21 — — EP disclosed
US-20040192653-A1 P38 inhibitors and methods of use thereof ARRAY BIOPHARMA INC. 2004-09-30 — — US disclosed
WO-2004078116-A2 P38 INHIBITORS AND METHODS OF USE THEREOF ARRAY BIOPHARMA, INC. (US) 2004-09-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP CTSK 1562/4885CTSS 2238/4885CYP1A2 3207/4885
US-20040192653-A1 P38 inhibitors and methods of use thereof MAPK1, MAPK3, MAPK8 CTSK 2205/4885CTSS 3593/4885CYP1A2 2617/4885
US-12110286-B2 Benzimidazolone derived inhibitors of BCL6 BCL6, BCL6B, BCL3 CTSK 1427/4885CTSS 2371/4885CYP1A2 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback